277 related articles for article (PubMed ID: 28522682)
1. Regorafenib Approved for Liver Cancer.
Cancer Discov; 2017 Jul; 7(7):660. PubMed ID: 28522682
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib: A Review in Hepatocellular Carcinoma.
Heo YA; Syed YY
Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib as treatment for patients with advanced hepatocellular cancer.
Thillai K; Srikandarajah K; Ross P
Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
Kyrochristos ID; Ziogas DE; Roukos DH
Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
[No Abstract] [Full Text] [Related]
7. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers.
Fondevila F; Méndez-Blanco C; Fernández-Palanca P; González-Gallego J; Mauriz JL
Exp Mol Med; 2019 Sep; 51(9):1-15. PubMed ID: 31551425
[TBL] [Abstract][Full Text] [Related]
9. Review article: systemic treatment of hepatocellular carcinoma.
Pinter M; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
Yoshioka N; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
Intern Med; 2019 Oct; 58(19):2803-2808. PubMed ID: 31243207
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
da Fonseca LG; Reig M; Bruix J
Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
Kim K; Jha R; Prins PA; Wang H; Chacha M; Hartley ML; He AR
Cancer Chemother Pharmacol; 2017 Nov; 80(5):945-954. PubMed ID: 28932966
[TBL] [Abstract][Full Text] [Related]
14. New Approvals in Cancer Treatment.
Aschenbrenner DS
Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749878
[No Abstract] [Full Text] [Related]
15. Hepatocellular carcinoma: Current situation and challenge.
Li Z; Zhu JY
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):303-304. PubMed ID: 31253577
[No Abstract] [Full Text] [Related]
16. Regorafenib: a promising treatment for hepatocellular carcinoma.
Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
[No Abstract] [Full Text] [Related]
17. Regorafenib for the treatment of hepatocellular carcinoma.
Tovoli F; Granito A; De Lorenzo S; Bolondi L
Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
19. Immune oncology in hepatocellular carcinoma-hype and hope.
Wörns MA; Galle PR
Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
[No Abstract] [Full Text] [Related]
20. The role of regorafenib in hepatocellular carcinoma.
Frenette CT
Clin Adv Hematol Oncol; 2017 Feb; 15(2):121-123. PubMed ID: 28398282
[No Abstract] [Full Text] [Related]
[Next] [New Search]
